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duced from proteins/amino acids.
In patientswith CKD, plasma levels of indoxyl sulfate (IS) and p-cresyl
sulfate (PCS) are 54 and 17 times higher, respectively, than in healthy in-
dividuals. Both IS and PCS are associated with accelerated progression to
dialysis and cardiovascular risk among pre-end-stage renal disease
(ESRD) patients (Lin et al., 2014; Lin et al., 2015a). Indoxyl sulfate isThe understanding of the role of nutrition in atherosclerosis has
been revolutionized by the recognition of effects of the intestinal
microbiome. Intestinal bacteria ferment nutrients into metabolic prod-
ucts, with profound effects on atherosclerosis and on cardiovascular
risk.
Carnitine from redmeat (~4 times asmuch as in chicken or ﬁsh) and
choline, including phosphatidylcholine from egg yolk, are converted by
the intestinal microbiome into trimethylamine (Wang et al., 2011;
Koeth et al., 2013), the compound that causes the ﬁshy odor in uremic
breath. Trimethylamine is oxidized in the liver to trimethylamine N-
oxide (TMAO), which causes atherosclerosis in an animal model
(Wang et al., 2011), and markedly increases cardiovascular risk.
That the TMAO results from fermentation by intestinal bacteria was
shown in animal model and in human subjects by giving antibiotics to
eliminate the intestinal bacteria. Perhaps the most interesting thing
about these studies was that vegans given carnitine did not product
TMAO, apparently lacking the “meat-eating” bacteria that do so
(Koeth et al., 2013). This suggests that it may be possible to modify
the intestinal microbiome, by a process similar to “repopulation” com-
monly used to treat clostridium difﬁcile.
Among patients referred for coronary angiogram, TMAO levels were
measured after a test dose of two hard-boiled eggs. Patients with TMAO
in the top quartile had 2.5 times higher three-year risk of stroke, myo-
cardial infarction or vascular death compared to those in the lowest
quartile (Tang et al., 2013).
The metabolic products of the intestinal microbiome are to a great
extent eliminated by the kidneys; they therefore accumulate in patients
with renal failure, and may be termed gut-derived uremic toxins
(GDUT). Homocysteine, a leading candidate to explain high cardiovas-
cular risk in uremia, appears to account for only ~20% of the excess ca-
rotid atherosclerosis in renal failure (Spence et al., 2016). Levels of
TMAO are high in renal failure, and besides increasing cardiovascular
risk, also accelerate decline of renal function (Tang et al., 2015). Besidesom.2016.10.030.
. This is an open access article underTMAO from carnitine and phosphatidylcholine, there are a number pro-
also associated with increased all-cause mortality, and with glycation
end products (Lin et al., 2015b).
Cardiovascular risk is very high in patients with renal failure
(Gansevoort et al., 2013), so for patients with renal failure it is particu-
larly important to avoid red meat and egg yolks.
Besides the metabolic products of the intestinal microbiome, it
seems that there are other non-metabolic pathways by which “gut mi-
crobes can also signal to the host to regulate innate immunity through
metabolism-independent pathways, where constituents of themicrobi-
al cell wall are sensed by host cells through pattern recognition recep-
tors to further impact CVD progression.”
In this issue of the journal EBioMedicine, Chen et al. (2016) report
what appears to be a metabolism-independent mechanism by which
the intestinal microbiome can affect atherosclerosis. They found that ef-
fects of the intestinal microbiome resulted in recruitment and ectopic
activation of B2 cells in perivascular adipose tissue and an increase in
circulating IgG, increasing development of atherosclerosis. This was
prevented by antibiotic elimination of the intestinal microbiome, and
also by depletion of B2 cells with antibodies.
There is more to be discovered about this story, but already it is clear
that the intestinal microbiome has important effects on atherosclerosis
and cardiovascular risk. Learning how to mitigate these effects will be
an important ﬁeld of research in the coming years.Disclosure
The author declared no conﬂicts of interest.References
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